Virus levels have risen across the country, fueled by ever-more-contagious omicron subvariants such as BA. 5 that evade some immune protections and have increased the risk of reinfections.
Officials warn of a possible fall or winter wave—perhaps as many as 100 million infections in the United States—that could again flood hospitals with COVID patients.
The agreement comes one day after the FDA placed a hold on its initial order banning Juul’s products from the market, saying that Juul’s application warranted “additional review.”
While lawmakers said total marijuana decriminalization is on the table for debate during summer study meetings, they will also explore restrictions involving the sale of products like delta-8, including age requirements for purchasing.
Reacting to a surprising and growing monkeypox outbreak, U.S. health officials on Tuesday expanded the group of people recommended to get vaccinated against the monkeypox virus.
A commission tasked with reviewing Indiana’s public health infrastructure has found spending per capita lags and is set to pitch a significant investment.
The FDA is considering ordering a recipe change for the vaccines made by both Pfizer and rival Moderna in hopes that modified boosters could better protect against another COVID surge expected this fall and winter.
In a new phase of long-term strategies, businesses can consider a metrics-based approach, lobby legislators and local officials to rely on evidence, provide employees and customers with predictability around mask-wearing, and protect health and business operations.
The researchers used data from 185 countries to estimate that vaccines prevented 4.2 million COVID-19 deaths in India, 1.9 million in the United States, 1 million in Brazil, 631,000 in France and 507,000 in the United Kingdom.
The action is part of a sweeping effort by the Food and Drug Administration to bring scientific scrutiny to the multibillion-dollar vaping industry after years of regulatory delays.
The panel unanimously recommended certain flu vaccines that might offer more or longer protection for seniors, whose weakened immune systems don’t respond as well to traditional shots.
COVID-19 vaccine makers are studying updated boosters that might be offered in the fall to better protect people against future coronavirus surges.
The advance toward a vaccine for infants, toddlers and preschoolers has been an achingly slow and incremental process, with pediatricians and families waiting for an opportunity to vaccinate young children.
Administration officials say they’re running low on money to stock up on, or even begin to order, the latest vaccines, tests and treatments. Also lacking are funds to reimburse doctors treating uninsured patients and to help poor countries control the pandemic.
Despite a nationwide surge in COVID-19 cases, deaths from the virus have remained largely stable over the past eight weeks.
This week, the Centers for Disease Control and Prevention released new estimates of the syndrome’s toll in the United States, suggesting it affects one in five adults younger than 65 who had COVID, and one in four of those aged 65 and older.
Pfizer plans to give the data to U.S. regulators later this week in a step toward letting the littlest children get the shots. The 18 million tots under 5 make up the only group in the U.S. not yet eligible for COVID-19 vaccination.
There is one more hurdle: The Centers for Disease Control and Prevention must decide whether to formally recommend the booster for this age group. The CDC’s scientific advisers are scheduled to meet on Thursday.
The U.S. is averaging about 300 COVID-19 deaths per day, compared with a peak of about 3,400 a day in January 2021.
White House COVID-19 coordinator Dr. Ashish Jha issued a dire warning Thursday that the U.S. will be increasingly vulnerable to the coronavirus this fall and winter if Congress doesn’t swiftly approve new funding for more vaccines and treatments.
